The discovery of a direct molecular target for vitamin C's anti-aging effects could transform how we approach longevity interventions. Rather than relying on its antioxidant properties alone, this research reveals vitamin C specifically inhibits the enzyme ACSL4, which orchestrates a newly identified aging pathway called "ferro-aging." This finding provides the first mechanistic explanation for why vitamin C supplementation might extend healthspan in humans.
The research team identified a conserved iron-lipid pathway that drives aging across primate species. As organisms age, iron accumulates in tissues, fueling chronic lipid peroxidation through the enzyme ACSL4. Unlike acute ferroptosis (iron-mediated cell death), this ferro-aging process promotes cellular senescence and gradual functional decline. When researchers administered vitamin C to aged monkeys for over 40 months, they observed potent reduction in ferro-aging markers across multiple tissues, improved neurological and metabolic function, and measurable reversal of biological age according to multi-omic aging clocks.
This work represents a significant advance in aging biology by identifying a specific, druggable target rather than broad antioxidant effects. The 40-month duration in non-human primates provides compelling translational evidence, as previous anti-aging research has largely relied on short-term studies or rodent models. However, the optimal dosing for humans remains unclear, and the research doesn't address whether synthetic ACSL4 inhibitors might prove more effective than vitamin C supplementation. The identification of ferro-aging as a core mechanism suggests multiple therapeutic approaches beyond vitamin C could emerge, potentially opening new avenues for targeted longevity interventions.
